156 related articles for article (PubMed ID: 11989627)
1. Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations.
Hannongbua S; Prasithichokekul S; Pungpo P
J Comput Aided Mol Des; 2001 Nov; 15(11):997-1004. PubMed ID: 11989627
[TBL] [Abstract][Full Text] [Related]
2. Structural flexibility of non-nucleoside HIV-1 reverse transcriptase inhibitor: 9-Cl TIBO as explained by potential energy surface and (13)C and (1)H NMR calculations, based on ab initio and density functional study.
Saen-Oon S; Hannongbua S; Wolschann P
J Chem Inf Comput Sci; 2003; 43(5):1412-22. PubMed ID: 14502474
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
[TBL] [Abstract][Full Text] [Related]
4. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
5. Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force field approaches and predictions of the effect of mutations on binding.
Raju RK; Burton NA; Hillier IH
Phys Chem Chem Phys; 2010 Jul; 12(26):7117-25. PubMed ID: 20480085
[TBL] [Abstract][Full Text] [Related]
6. Conformational study of the HIV-1 reverse transcriptase inhibitor 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
Lawtrakul L; Hannongbua S; Beyer A; Wolschann P
Biol Chem; 1999 Feb; 380(2):265-7. PubMed ID: 10195434
[TBL] [Abstract][Full Text] [Related]
7. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
Treesuwan W; Hannongbua S
J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
10. A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
Dyatkin AB; Brickwood JR; Proudfoot JR
Bioorg Med Chem Lett; 1998 Aug; 8(16):2169-72. PubMed ID: 9873507
[TBL] [Abstract][Full Text] [Related]
11. Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations.
He X; Mei Y; Xiang Y; Zhang DW; Zhang JZ
Proteins; 2005 Nov; 61(2):423-32. PubMed ID: 16114038
[TBL] [Abstract][Full Text] [Related]
12. Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutants.
Saparpakorn P; Hannongbua S; Rognan D
SAR QSAR Environ Res; 2006 Apr; 17(2):183-94. PubMed ID: 16644557
[TBL] [Abstract][Full Text] [Related]
13. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
14. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
[TBL] [Abstract][Full Text] [Related]
15. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
Rizzo RC; Tirado-Rives J; Jorgensen WL
J Med Chem; 2001 Jan; 44(2):145-54. PubMed ID: 11170624
[TBL] [Abstract][Full Text] [Related]
16. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Zhou T; Xie L
Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
[No Abstract] [Full Text] [Related]
17. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
Medina-Franco JL; Rodríguez-Morales S; Juárez-Gordiano C; Hernández-Campos A; Jiménez-Barbero J; Castillo R
Bioorg Med Chem; 2004 Dec; 12(23):6085-95. PubMed ID: 15519154
[TBL] [Abstract][Full Text] [Related]
18. Conformational analysis of the anti-HIV Nikavir prodrug: comparisons with AZT and Thymidine, and establishment of structure-activity relationships/tendencies in other 6'-derivatives.
El-Sayed AA; Tamara Molina A; Álvarez-Ros MC; Alcolea Palafox M
J Biomol Struct Dyn; 2015; 33(4):723-48. PubMed ID: 24762127
[TBL] [Abstract][Full Text] [Related]
19. Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase.
Titmuss SJ; Keller PA; Griffith R
Bioorg Med Chem; 1999 Jun; 7(6):1163-70. PubMed ID: 10428388
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
